JPMorgan Chase & Co. Reiterates “Neutral” Rating for Novartis (NVS)
Other equities research analysts have also issued research reports about the stock. Zacks Investment Research lowered shares of Novartis from a buy rating to a hold rating in a report on Friday, October 6th. Leerink Swann upped their target price on shares of Novartis from $89.00 to $91.00 and gave the stock a market perform rating in a report on Monday, October 23rd. Nord/LB restated a neutral rating on shares of Novartis in a report on Tuesday, January 2nd. UBS Group restated a neutral rating on shares of Novartis in a report on Monday, January 15th. Finally, Bank of America lowered shares of Novartis from a neutral rating to an underperform rating in a report on Wednesday, December 6th. Five investment analysts have rated the stock with a sell rating, eight have given a hold rating and four have given a buy rating to the stock. Novartis currently has a consensus rating of Hold and a consensus price target of $85.32.
Shares of Novartis (NYSE:NVS) traded up $0.53 during midday trading on Thursday, hitting $86.94. 770,420 shares of the stock traded hands, compared to its average volume of 801,800. Novartis has a 52-week low of $69.53 and a 52-week high of $87.29. The firm has a market capitalization of $204,411.06, a price-to-earnings ratio of 30.94, a P/E/G ratio of 2.31 and a beta of 0.73. The company has a quick ratio of 0.81, a current ratio of 1.08 and a debt-to-equity ratio of 0.32.
Hedge funds have recently modified their holdings of the business. Cetera Investment Advisers bought a new stake in Novartis in the 2nd quarter worth about $241,000. Bartlett & Co. LLC grew its position in Novartis by 1.6% in the 3rd quarter. Bartlett & Co. LLC now owns 473,081 shares of the company’s stock worth $40,614,000 after purchasing an additional 7,249 shares in the last quarter. Capital Bank & Trust Co grew its position in Novartis by 5.5% in the 3rd quarter. Capital Bank & Trust Co now owns 138,207 shares of the company’s stock worth $11,865,000 after purchasing an additional 7,201 shares in the last quarter. Atlantic Trust Group LLC grew its position in Novartis by 54.2% in the 3rd quarter. Atlantic Trust Group LLC now owns 72,427 shares of the company’s stock worth $6,218,000 after purchasing an additional 25,452 shares in the last quarter. Finally, Cedar Hill Associates LLC bought a new stake in Novartis in the 3rd quarter worth about $248,000. 10.85% of the stock is owned by institutional investors and hedge funds.
Novartis Company Profile
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.